SCHEMBL14947703

SCHEMBL14947703

CC(C)(C)OC(=O)n1ncc(N)n1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.35
NR1H2 P55055 2/20 0.35
BCHE P06276 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
FAAH O00519 1/20 0.33
ROCK2 O75116 1/20 0.33
GPR119 Q8TDV5 2/20 0.32
MAP4K4 O95819 1/20 0.32
SCN9A Q15858 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PTPN11 Q06124 1/20 0.32
SMARCA2 P51531 1/20 0.32
SMARCA4 P51532 1/20 0.32
PBRM1 Q86U86 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14947705 0.74 LMNA (0.40) ELANEBCHESMN1; SMN2
SCHEMBL30806143 0.71 CTSD (0.47) GPR119
SCHEMBL27997377 0.71 USP2 (0.38) ELANENR1H2BCHEFAAHGPR119
SCHEMBL29196133 0.70 FAAH (0.41) NR1H2BCHEHSP90AA1HSP90AB1FAAH
SCHEMBL306662 0.69 HSP90AA1 (0.39) NR1H2BCHEHSP90AA1HSP90AB1FAAH
SCHEMBL671541 0.69 ROCK2 (0.45) ELANENR1H2BCHEHSP90AA1HSP90AB1
SCHEMBL25293645 0.68 ELANE (0.43) ELANENR1H2BCHEHSP90AA1HSP90AB1
SCHEMBL161429 0.68 FAAH (0.39) ELANENR1H2BCHEHSP90AA1HSP90AB1
SCHEMBL15502407 0.68 ELANE (0.43) ELANENR1H2BCHEHSP90AA1HSP90AB1
SCHEMBL2480409 0.67 FAAH (0.38) ELANENR1H2BCHEHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013071232-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF TBL-1 BINDING TO DISEASE-ASSOCIATED MOLECULES BETA CAT PHARMACEUTICALS, LLC (US) 2013-05-16 WO disclosed
US-20130123281-A1 Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules BETA CAT PHARMACEUTICALS, LLC (US) 2013-05-16 US disclosed
US-20130123281-A1 Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules BETA CAT PHARMACEUTICALS, LLC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123281-A1 Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules TBL2, TBL3, TBL1XR1 ELANE 2024/4885NR1H2 1225/4885BCHE 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.